Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model

Neuroscience

Volumn 298, Issue , 2015, Pages 424-435

  Reid, G Andrew ^a   Darvesh, Sultan ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

5XFAD mouse; Alzheimer's disease; Butyrylcholinesterase; Butyrylcholinesterase knockout; Cholinergic system; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE; PRESENILIN 1; AMYLOID;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; AGE; ANIMAL; BRAIN; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; BUTYRYLCHOLINESTERASE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PRESENILIN-1;

EID: 84928901691     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.04.039     Document Type: Article

References (70)

1. Alves-Amaral G., Pires-Oliveira M., Andrade-Lopes A., Chiavegatti T., Godinho R.O. Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: Effects of sex hormone withdrawal. Chem Biol Interact 2010, 186:9-15.
2. Alzheimer's Association Alzheimer's disease facts and figures. Alzheimer's Dement 2014, 10(2):e47-92.
3. Atack J.R., Perry E.K., Bonham J.R., Candy J.M., Perry R.H. Molecular forms of butyrylcholinesterase in the human neocortex during development and degeneration of the cortical cholinergic system. J Neurochem 1987, 48:1687-1692.
4. Barnes L.L., Wilson R.S., Bienias J.L., Schneider J.A., Evans D.A., Bennett D.A. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry 2005, 62(6):685-691.
5. Bartels C.F., Jensen F.S., Lockridge O., van der Spek A.F.L., Rubinstein H.M., Lubrano T., La Du B.N. DNA Mutation Associated with the Human Butyrylcholinesterase K-Variant and Its Linkage to the Atypical Variant Mutation and Other Polymorphic Sites. Am J Hum Genet 1992, 50:1086-1103.
6. Baulieu E.E., Robel P. Neurosteroids: a new brain function?. J Steroid Biochem Mol Biol 1990, 37(3):395-403.
7. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
8. Brinton R.D., Tran J., Proffitt P., Montoya M. 17 beta-Estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem Res 1997, 22(11):1339-1351.
9. Carroll J.C., Rosario E.R., Kreimer S., Villamagna A., Gentzschein E., Stanczyk F.Z., Pike C.J. Sex differences in β-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure. Brain Res 2010, 1366:233-245.
10. Carroll J.C., Rosario E.R., Chang L., Stanczyk F.Z., Oddo S., LaFerla F.M., Pike C.J. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci 2007, 27(48):13357-13365.
11. Combarros O., Riancho J.A., Arozamena J., Mateo I., Llorca J., Infante J., Sánchez-Juan P., Zarrabeitia M.T., Berciano J. Interaction between estrogen receptor-alpha and butyrylcholinesterase genes modulates Alzheimer's disease risk. J Neurol 2007, 254(9):1290-1292.
12. Combarros O., Riancho J.A., Infante J., Sañudo C., Llorca J., Zarrabeitia M.T., Berciano J. Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk. Dement Geriatr Cogn Disord 2005, 20(2-3):153-157.
13. Corder E.H., Ghebremedhin E., Taylor M.G., Thal D.R., Ohm T.G., Braak H. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci 2004, 1019:24-28.
14. Darvesh S., Geula G., Hopkins D.A. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003, 4:131-138.
15. Darvesh S., Reid G.A., Martin E. Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues. Curr Alzheimer Res 2010, 7:386-400.
16. Darvesh S., Cash M.K., Reid G.A., Martin E., Mitniski A., Geula C. Butyrylcholinesterase, β-amyloid and Thioflavin-S Plaques in the Transgenic APPSWE/PSEN1dE9 mouse Model of Alzheimer's Disease. J Neuropathol Exp Neurol 2012, 71(1):2-14.
17. Diamant S., Podoly E., Friedler A., Ligumsky H., Livnah O., Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2006, 103(23):8628-8633.
18. Do Rego J.L., Seong J.Y., Burel D., Leprince J., Luu-The V., Tsutsui K., Tonon M.C., Pelletier G., Vaudry H. Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front Neuroendocrinol 2009, 30(3):259-301.
19. Duysen E.G., Li B., Darvesh S., Lockridge O. Sensitivity of butyrylcholinesterase knockout mice to (-)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology 2007, 233(1-3):60-69.
20. Eberling J.L., Wu C., Haan M.N., Mungas D., Buonocore M., Jagust W.J. Preliminary evidence that estrogen protects against age-related hippocampal atrophy. Neurobiol Aging 2003, 24(5):725-732.
21. Edwards J.A., Brimijoin S. Effects of hypophysectomy on acetylcholinesterase and butyrylcholinesterase in the rat. Biochem Pharmacol 1983, 32(7):1183-1189.
22. Geula C., Mesulam M.M. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 1995, 2:23-28.
23. Geula C., Mesulam M.M. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res 1989, 498:185-189.
24. Giacobini E. Butyrylcholinesterase: its function and inhibitors 2003, London and New York, Martin Dunitz.
25. Gibbs R.B. Estrogen and nerve growth factor-related systems in brain. Effects on basal forebrain cholinergic neurons and implications for learning and memory processes and aging. Ann N Y Acad Sci 1994, 743:156-196.
26. Gibbs R.B. Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev 2010, 31(2):224-253.
27. Gouras G.K., Xu H., Gross R.S., Greenfield J.P., Hai B., Wang R., Greengard P. Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci USA 2000, 97(3):1202-1205.
28. Greig NH, Yu Q-S, Brossi A, Martin E, Lahiri DK Darvesh S (2008). Butyrylcholinesterase, the Cinderella cholinesterase, as a drug target for Alzheimer's disease and related dementias. In: Medicinal chemistry of Alzheimer's disease, (Gil AM ed.), pp. 79-109 Kerala, India: Transworld Research Network.
29. Grubber J.M., Saunders A.M., Crane-Gatherum A.R., Scott W.K., Martin E.R., Haynes C.S., Conneally P.M., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). Neurosci Lett 1999, 269:115-119.
30. Guillozet A.L., Smiley J.F., Mash D.C., Mesulam M.M. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997, 42:909-918.
31. Henderson V.W., Buckwalter J.G. Cognitive deficits of men and women with Alzheimer's disease. Neurology 1994, 44:90-96.
32. Hiltunen M., Mannermaa A., Helisalmi S., Koivisto A., Lehtovirta M., Ryynänen M., Riekkinen P.S., Soininen H. Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients. Neurosci Lett 1998, 250(1):69-71.
33. Hirata-Fukae C., Li H.F., Hoe H.S., Gray A.J., Minami S.S., Hamada K., Niikura T., Hua F., Tsukagoshi-Nagai H., Horikoshi-Sakuraba Y., Mughal M., Rebeck G.W., LaFerla F.M., Mattson M.P., Iwata N., Saido T.C., Klein W.L., Duff K.E., Aisen P.S., Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res 2008, 1216:92-103. doi: 10.1016.
34. Hojo Y., Hattori T.A., Enami T., Furukawa A., Suzuki K., Ishii H.T., Mukai H., Morrison J.H., Janssen W.G., Kominami S., Harada N., Kimoto T., Kawato S. Adult male rat hippocampus synthesizes estradiol from pregnenolone by cytochromes P45017alpha and P450 aromatase localized in neurons. Proc Natl Acad Sci USA 2004, 101(3):865-870.
35. Illsley N.P., Lamartiniere C.A. Endocrine regulation of rat serum cholinesterase activity. Endocrinology 1981, 108(5):1737-1743.
36. Irvine K., Laws K.R., Gale T.M., Kondel T.K. Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol 2012, 34(9):989-998.
37. Karnovsky M.J., Roots L.A. "Direct-coloring" thiocholine method for cholinesterases. J Histochem Cytochem 1964, 12:219-221.
38. Kehoe P.G., Williams H., Holmans P., Wilcock G., Cairns N.J., Neal J., Owen M.J. The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease. J Med Genet 1998, 35:1034-1035.
39. Ki C.-S., Na D.L., Kim J.-W., Kim H.J., Kim D.K., Yoon B.-K. No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease. Am J Med Genet 1999, 88:113-115.
40. Lehmann D.J., Nagy Z., Litchfield S., Borja C., Smith A.D. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Hum Genet 2000, 106:447-452.
41. Lehmann D.J., Williams J., Mcbroomc J., Smith A.D. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience 2001, 108:541-554.
42. Li B., Duysen E.G., Saunders T.L., Lockridge O. Production of the butyrylcholinesterase knockout mouse. J Mol Neurosci 2006, 30(1-2):193-195.
43. Li B., Duysen E.G., Carlson M., Lockridge O. The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency. J Pharmacol Exp Ther 2008, 324(3):1146-1154.
44. Li R., Singh M. Sex differences in cognitive impairment and Alzheimer's disease. Front Neuroendocrinol 2014, 35(3):385-403.
45. Lorenzen A., Samosh J., Vandewark K., Anborgh P.H., Seah C., Magalhaes A.C., Cregan S.P., Ferguson S.S., Pasternak S.H. Rapid and direct transport of cell surface APP to the lysosome defines a novel selective pathway. Mol Brain 2010, 3:11.
46. Malsbury C.W., McKay K. Neurotrophic effects of testosterone on the medial nucleus of the amygdala in adult male rats. J Neuroendocrinol 1994, 6(1):57-69.
47. Masters C.L., Selkoe D.J. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2012, 10.1101/cshperspect.a006262.
48. McIlroy S.P., Crawford V.L.S., Dynan K.B., McGleenon B.M., Vahidassr M.D., Lawson J.T., Passmore A.P. Butyrylcholinesterase K variant is genetically associated with late-onset Alzheimer's disease in Northern Ireland. J Med Genet 2000, 37:182-185.
49. Mesulam M.M., Guillozet A., Shaw P., Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002, 9(1):88-93.
50. Mesulam M.M., Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994, 36:722-727.
51. Mielke M.M., Vemuri P., Rocca W.A. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol 2014, 6:37-48.
52. Mundell D.B. Plasma cholinesterase in male and female rats. Nature 1944, 3888(153):557-558.
53. O'Brien K.K., Saxby B.K., Ballard C.G., et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 2003, 13:231-239.
54. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006, 26:10129-10140.
55. Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Changes in brain cholinesterases in senile dementia of the Alzheimer type. Neuropathol Appl Neurobiol 1978, 4:273-277.
56. Plassman B.L., Langa K.M., Fisher G.G., Heeringa S.G., Weir D.R., Ofstedal M.B., et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007, 29:125-132.
57. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N Engl J Med 2010, 362(4):329-344.
58. Ramanan V.K., Risacher S.L., Nho K., Kim S., Swaminathan S., Shen L., Foroud T.M., Hakonarson H., Huentelman M.J., Aisen P.S., Petersen R.C., Green R.C., Jack C.R., Koeppe R.A., Jagust W.J., Weiner M.W., Saykin A.J. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry 2014, 19(3):351-357. Alzheimer's Disease Neuroimaging Initiative. 10.1038/mp.2013.19.
59. Rosario E.R., Carroll J., Pike C.J. Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways. Brain Res 2010, 1359:281-290.
60. Sandbrink R., Gasperina A., Zerfass R., Weber B., Masters C.L., Beyreuther K., Heuser I. Butyrylcholinesterase K variant (BCHE-K): association with late-onset Alzheimer's disease. Neurobiol Aging 1998, 19:S69.
61. Seshadri S., Wolf P.A., Beiser A., Au R., McNulty K., White R., D'Agostino R.B. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham study. Neurology 1997, 49(6):1498-1504.
62. Sinforiani E., Citterio A., Zucchella C., Bono G., Corbetta S., Merlo P., Mauri M. Impact of gender differences on the outcome of Alzheimer's disease. Dement Geriatr Cogn Disord 2010, 30(2):147-154.
63. Singleton A.B., Smith G., Gibson A.M., Woodward R., Perry R.H., Ince P.G., Edwardson J.A., Morris C.M. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum Mol Genet 1998, 7:937-939.
64. Stanić D., Dubois S., Chua H.K., Tonge B., Rinehart N., Horne M.K., Boon W.C. Characterization of aromatase expression in the adult male and female mouse brain. I. Coexistence with oestrogen receptors α and β, and androgen receptors. PLoS One 2014, 9(3):e90451.
65. Tilley L., Morgan K., Grainger J., Marsters P., Morgan L., Lowe J., Xuereb J., Wischik C., Harrington C., Kalsheker N. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. Eur J Hum Genet 1999, 7:659-663.
66. Truett G.E., Heeger P., Mynatt R.L., Truett A.A., Walker J.A., Warman M.L. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 2000, 29:52-54.
67. Vest R.S., Pike C.J. Gender, sex steroid hormones, and Alzheimer's disease. Horm Behav 2013, 63:301-307.
68. Wiebusch H., Poirier J., Sévigny P., Schappert K. Further evidence for a synergistic association between APOEe4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet 1999, 104:158-163.
69. Xing Y., Jia J.P., Ji X.J., Tian T. Estrogen associated gene polymorphisms and their interactions in the progress of Alzheimer's disease. Prog Neurobiol 2013, 111:53-74.
70. Yamamoto Y., Yasuda M., Mori E., Maeda K. Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the e4 allele of the apolipoprotein gene in Japanese patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999, 67:94-96.